Ignite Creation Date:
2024-07-17 @ 11:14 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463626
Status:
COMPLETED
Last Update Posted:
2024-06-18
First Post:
2024-06-10
Brief Title:
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
REal-world Patterns of Treatment With CDKi 46 for AdVanced BrEast CAncer in PortugaL - REVEAL Study
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a non-interventional observational retrospective cohort study of women with hormone receptor HR-positive and human epidermal growth factor receptor-type 2 HER2-negative advanced breast cancer who started treatment with cyclin-dependent kinase inhibitors CDKi 46 ribociclib or palbociclib in Portugal This was a study of medication use patterns based on information from the hospital pharmacies of the participating centers
Patients who started a CDKi 46 ribociclib or palbociclib between 1 March 2019 and 31 December 2019 were included and followed through 24 months A follow-up occurred 6 months after the start of CDKi 46 ribociclib or palbociclib to quantify the occurrence of dose changes
Patients who started a CDKi 46 ribociclib or palbociclib between 1 March 2019 and 31 December 2019 were included and followed through 24 months A follow-up occurred 6 months after the start of CDKi 46 ribociclib or palbociclib to quantify the occurrence of dose changes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: